

COMMITTED TO
PHYSICIANS |



Business banking advice and solutions tailored to physicians.

Our mobile Healthcare Specialists understand the unique financial needs of starting, managing and growing your medical practice. We have the business banking expertise to provide you with tailored advice and solutions through the Scotiabank Healthcare+ Physician Banking Program.

Visit scotiabankhealthcareplus.com

All banking and credit products and services available through the Scotiabank Healthcare+ Physician Banking Program are offered by The Bank of Nova Scotia (Scotiabank). Credit and lending products are subject to credit approval by Scotiabank.

® Registered Trademark of The Bank of Nova Scotia.

Scotiabank[®]
Healthcare+

**Assistant Professor
Neurologist
University of Toronto
Sinai Health System and University Health Network**

The Division of Neurology, Department of Medicine, University Health Network/Sinai Health System (UHN/SHS) at the University of Toronto is seeking Clinician Teacher/Investigator/Quality Improvement Neurologist(s) with a focus on general neurology and general neurology with an interest in women's neurology. The candidate(s) must be eligible for a full-time clinical academic appointment at the rank of Assistant Professor or higher at the University of Toronto. The effective start date is negotiable.

The successful candidate will hold an MD degree and should have, or be eligible for, certification in Neurology by the Royal College of Physicians and Surgeons of Canada and licensure with the College of Physicians and Surgeons of Ontario (CPSO). He or she will have established expertise in clinical care in general neurology. Additional clinical expertise in the neurological disorders of women (including obstetrics, stroke, headache) would be encouraged. He or she will have specific additional training such as a Master's degree or equivalent. The successful candidate will develop General Neurology services for inpatient and ambulatory care consults and be based at Sinai Health Systems. Other duties may include EMG/NCS expertise. Teaching duties will include post graduate residents and undergraduate medical students as per Division of Neurology. The successful candidate will participate in all aspects of the UHN/SHS Neuroscience Program. Academic appointment will be in the Division of Neurology, Department of Medicine University of Toronto and salary will be commensurate with training and experience.

Applications will be accepted until Sept 30th 2021.

Please send curriculum vitae, names of three referees and a letter of application to:

Susan Fox MRCP(UK), PhD, Professor of Neurology, University of Toronto
Director, Division of Neurology, University Health Network and Sinai Health System
Movement Disorder Clinic, Toronto Western Hospital,
399, Bathurst St, Toronto ON, Canada M5T 2S8
Susan.Fox@uhnresearch.ca

For more information about the Department of Medicine please visit <http://www.deptmedicine.utoronto.ca>. The University of Toronto is strongly committed to diversity within its community and especially welcomes applications from racialized persons / persons of colour, women, Indigenous / Aboriginal People of North America, persons with disabilities, LGBTQ2S+ persons, and others who may contribute to the further diversification of ideas.

All qualified candidates are encouraged to apply; however, Canadians and permanent residents will be given priority.


A new name in MIGRAINE PREVENTION

Introducing

 **vyepti**[®]

eptinezumab for injection
100 mg/mL

**The 1st and only IV treatment administered every 12 weeks
indicated in migraine prevention***

SIGN UP FOR UPDATES AT 

www.vyepti.ca/en/signup

*Comparative clinical significance is unknown.

VYEPTI[®] (eptinezumab for injection) is indicated for the prevention of migraine in adults who have at least 4 migraine days per month. VYEPTI[®] should be prescribed by healthcare professionals experienced in the diagnosis and treatment of migraine. Consult the product monograph at <https://www.lundbeck.com/ca/en/our-products/our-products-in-canada> for important information on contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling us at 1-800-586-2325.

Lundbeck



© Copyright 2021 Lundbeck. All rights reserved.
VYEPTI[®] is a registered trademark owned by H. Lundbeck A/S,
used under license by Lundbeck Canada Inc.

VYE-B-100002-E



**Stroke Neurologist
University of Toronto, Krembil Brain Institute
University Health Network/Sinai Health System**

The Division of Neurology, Department of Medicine, University Health Network/Sinai Health System (UHN/SHS), University of Toronto is seeking a full-time, permanent Clinician in Quality Improvement/Investigator focussed on Stroke Neurology. The candidate must be eligible for a full-time clinical academic appointment at the rank of Assistant Professor or higher at the University of Toronto. Effective start date negotiable.

The successful candidate will hold a MD degree and have, or be eligible for, certification in Neurology by the Royal College of Physicians and Surgeons of Canada and licensure with the College of Physicians and Surgeons of Ontario. He or she will have specific additional training such as a Master's degree or equivalent. The candidate must have completed a Stroke Fellowship program and have established expertise in Stroke Neurology.

The candidate will participate in the Neurovascular Unit inpatient care, outpatient clinics and on-call pool for hyperacute stroke care. Teaching duties will be as per Division of Neurology requirements. Academic appointment will be within the Division of Neurology, Department of Medicine, University of Toronto.

Please send curriculum vitae, names of three referees and a letter of application to:

Susan Fox MRCP(UK), PhD, Professor of Neurology, University of Toronto
Director, Division of Neurology, University Health Network and Sinai Health System
Movement Disorder Clinic, Toronto Western Hospital,
399, Bathurst St, Toronto, ON, Canada M5T 2S8
Susan.Fox@uhnresearch.ca

Deadline 30th Sept 2021

For more information about the Department of Medicine please visit <http://www.deptmedicine.utoronto.ca>. The University of Toronto is strongly committed to diversity within its community and especially welcomes applications from racialized persons / persons of colour, women, Indigenous / Aboriginal People of North America, persons with disabilities, LGBTQ2S+ persons, and others who may contribute to the further diversification of ideas.

All qualified candidates are encouraged to apply; however, Canadians and permanent residents will be given priority.

Pr **wakix**®

Pitolisant hydrochloride tablets

AVAILABLE SOON!

Be the first to know!

Contact us at 1-888-867-7426 or medinfo@paladinlabs.com.



© Registered trademark of Bioprojet Europe Ltd
© 2021 Paladin Labs Inc. St-Laurent, QC. 1-888-867-7426. www.paladinlabs.com



Kesimpta[®]

ofatumumab

NOW AVAILABLE

POWER TO TREAT ACTIVE RRMS

defined by clinical and imaging features¹

KESIMPTA[®] (ofatumumab injection) is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.

**CHOOSE KESIMPTA[®] FOR YOUR
ADULT PATIENTS WITH ACTIVE RRMS.**

FLEXIBILITY OF SELF-ADMINISTERED INJECTIONS¹

- The first injection should be performed under the guidance of an experienced health professional.
- Self-administered subcutaneous injections for trained patients*
- The initial dose is 20 mg SC at weeks 0, 1 and 2, with subsequent monthly dosing of 20 mg SC at week 4.

Consult the KESIMPTA[®] Product Monograph for complete dosing considerations, including assessments before every injection and premedication.



 **NOVARTIS**

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval (Quebec) H9S 1A9
www.novartis.ca
Tel: 514-631-6775 Fax: 514-631-1867
Medical Information Tel: 1-800-363-8883

© 2021 Novartis Pharmaceuticals Canada Inc.
All rights reserved.
® Kesimpta is a registered trademark.
March/2021-106672E

Please consult the Product Monograph at www.novartis.ca/kesimptamonograph for important information related to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-363-8883 or by email at medinfo.canada@novartis.com.

References: 1. KESIMPTA[®] product monograph. Novartis. February 19, 2021.
SC=subcutaneous

* Administration should be performed by an individual who has been trained to administer the product.



Cambridge Core
For further information about this journal
please go to the journal website at:
[cambridge.org/cjn](https://www.cambridge.org/cjn)

CAMBRIDGE
UNIVERSITY PRESS